Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Adaptimmune Therapeutics Stock News

ADAPNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.2542

At close: Jun 17 EDT

$0.2506

-0.00360-1.42%

Pre-Market: 4:32 AM EDT

Adaptimmune Therapeutics (ADAP) Forecast

News

Earnings Adaptimmune Therapeutics (ADAP) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Adaptimmune Therapeutics Stock News | NASDAQ:ADAP | Benzinga

Get the latest news on Adaptimmune Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Adaptimmune Therapeutics performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, June 12, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights

Wednesday, May 14, 2025

Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics
Benzinga Insights
Barclays Maintains Underweight on Adaptimmune...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Adaptim...
Benzinga Newsdesk

Tuesday, May 13, 2025

ADAP stock has given up its prior gain. Adapt...
Benzinga Newsdesk
Adaptimmune Therapeutics shares are trading h...
Benzinga Newsdesk
Adaptimmune Therapeutics Q1 EPS $(0.03) Beats...
Benzinga Newsdesk
Earnings Scheduled For May 13, 2025
Benzinga Insights

Monday, May 12, 2025

A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast
Benzinga Insights

Wednesday, April 23, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Friday, April 04, 2025

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights

Tuesday, April 01, 2025

What Analysts Are Saying About Adaptimmune Therapeutics Stock
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Adaptimm...
Benzinga Newsdesk

Wednesday, March 26, 2025

Guggenheim Maintains Buy on Adaptimmune Thera...
Benzinga Newsdesk

Friday, March 21, 2025

Wells Fargo Maintains Equal-Weight on Adaptim...
Benzinga Newsdesk
Scotiabank Maintains Sector Outperform on Ada...
Benzinga Newsdesk

Thursday, March 20, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Adaptimmune Therapeutics shares are trading l...
Benzinga Newsdesk
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results
Avi Kapoor
Adaptimmune Says 2024 Annual Report, Set To B...
Benzinga Newsdesk
Earnings Scheduled For March 20, 2025
Benzinga Insights

Monday, January 13, 2025

Adaptimmune Reports Breakthrough Therapy Desi...
Benzinga Newsdesk

Monday, December 02, 2024

Adaptimmune Therapeutics Announces That The F...
Benzinga Newsdesk

Wednesday, November 27, 2024

Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
Benzinga Insights
Mizuho Maintains Outperform on Adaptimmune Th...
Benzinga Newsdesk

Tuesday, November 19, 2024

HC Wainwright & Co. Reiterates Buy on Adaptim...
Benzinga Newsdesk

Friday, November 15, 2024

Guggenheim Maintains Buy on Adaptimmune Thera...
Benzinga Newsdesk

Thursday, November 14, 2024

HC Wainwright & Co. Maintains Buy on Adaptimm...
Benzinga Newsdesk
Adaptimmune Therapeutics shares are trading l...
Benzinga Newsdesk

Wednesday, November 13, 2024

Adaptimmune Therapeutics Q3 2024 GAAP EPS $(0...
Benzinga Newsdesk
Trading Halt: Halt status updated at 4:30:00 ...
Benzinga Newsdesk
Trading Halt: Halted at 4:00:10 p.m. ET - Tra...
Benzinga Newsdesk
Adaptimmune To Present Data From Primary Anal...
Benzinga Newsdesk
Earnings Scheduled For November 13, 2024
Benzinga Insights

Tuesday, November 12, 2024

An Overview of Adaptimmune Therapeutics's Earnings
Benzinga Insights

Friday, November 01, 2024

Adaptimmune Therapeutics Receives Nasdaq Noti...
Benzinga Newsdesk

Tuesday, August 13, 2024

HC Wainwright & Co. Reiterates Buy on Adaptim...
Benzinga Newsdesk

Monday, August 12, 2024

Adaptimmune Therapeutics shares are trading h...
Benzinga Newsdesk
Adaptimmune Therapeutics Q2 2024 GAAP EPS $0....
Benzinga Newsdesk
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Avi Kapoor

Monday, August 05, 2024

The Latest Analyst Ratings For Adaptimmune Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Adaptim...
Benzinga Newsdesk

Friday, August 02, 2024

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Vandana Singh
Trading Halt: Halt status updated at 7:00:00 ...
Benzinga Newsdesk
Reported Earlier, Adaptimmune's TECELRA Gains...
Benzinga Newsdesk

Thursday, August 01, 2024

Trading Halt: Halted at 7:01:19 p.m. ET - Tra...
Benzinga Newsdesk

Tuesday, July 30, 2024

HC Wainwright & Co. Initiates Coverage On Ada...
Benzinga Newsdesk

Monday, June 17, 2024

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
Zacks Small Cap Research

Friday, May 31, 2024

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
Henry Khederian

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved